Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...

Novartis has responded ... of the IRA's approach to drug negotiations – said he was surprised at the inclusion of Entresto, as well as some others on the list, including AstraZeneca's Farxiga ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

For our list of best pharma stocks to buy according to short ... expire – requiring it to continuously launch new products. Novartis AG (NYSE:NVS)’s management shared key details for its ...

My colleague Ed Silverman, who I view as the foremost expert on drug patents (and coffee flavors ... The FDA yesterday approved Novartis’ Kisqali in combination with hormone therapy for ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals ... by MSN's generic ANDA product. The ’918 patent ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the ...